Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | USP8 | P40818 | 2/20 | 0.41 |
| ▸ | USP7 | Q93009 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785543 | 1.00 | KDM4E (0.64) | KDM4EMAPTTDP1L3MBTL1GAA | |
| SCHEMBL1752959 | 0.77 | KDM4E (0.50) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL16516055 | 0.76 | L3MBTL1 (0.50) | KDM4EMAPTTDP1L3MBTL1GAA | |
| SCHEMBL1918785 | 0.76 | MEN1 (0.55) | KDM4EMAPTTDP1L3MBTL1GAA | |
| SCHEMBL30785511 | 0.75 | KHK (0.44) | KDM4EMAPTTDP1L3MBTL1CNR1 | |
| SCHEMBL17498449 | 0.75 | KHK (0.44) | KDM4EMAPTTDP1L3MBTL1CNR1 | |
| SCHEMBL25378957 | 0.74 | KDM4E (0.53) | KDM4EMAPTTDP1CNR1CNR2 | |
| SCHEMBL3626666 | 0.73 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL101711 | 0.72 | TRPV4 (0.61) | KDM4EMAPTTDP1TP53 | |
| SCHEMBL25394131 | 0.71 | L3MBTL1 (0.48) | KDM4ETDP1L3MBTL1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2025-12-30 | — | — | US | disclosed |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-11-28 | — | — | US | disclosed |
| EP-3180002-B1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2022-04-20 | — | — | EP | disclosed |
| EP-3180002-B1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2022-04-20 | — | — | EP | disclosed |
| US-20210145839-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-05-20 | — | — | US | disclosed |
| US-20210145839-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-05-20 | — | — | US | disclosed |
| US-10888567-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-01-12 | — | — | US | disclosed |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2017-08-10 | — | — | US | disclosed |
| EP-3180002-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | Auckland Uniservices Limited (NZ) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024233-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016024233-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-02-18 | — | — | WO | disclosed |
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8664246-B2 | Substituted pyridines, and use thereof as GSK3 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| EP-2326639-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826316-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | KDM4E 768/4885MAPT 4310/4885TDP1 321/4885 |
| US-20240285641-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | KDM4E 768/4885MAPT 4310/4885TDP1 321/4885 |
| US-12508268-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, IDO2, TDO2 | KDM4E 1473/4885MAPT 4598/4885TDP1 841/4885 |
| US-20170224701-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | KDM4E 768/4885MAPT 4310/4885TDP1 321/4885 |
| US-20210145839-A1 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | IDO1, TDO2, IDO2 | KDM4E 768/4885MAPT 4310/4885TDP1 321/4885 |
| US-20110190316-A1 | Substituted pyridines, and use thereof as Gsk3 inhibitors | GSK3B, GSK3A, GSKIP | KDM4E 620/4885MAPT 1901/4885TDP1 1112/4885 |
| US-10888567-B2 | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy | IDO1, TDO2, IDO2 | KDM4E 768/4885MAPT 4310/4885TDP1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.